CO6650337A2 - Derivados de 3- hidroxi-5 -arilisotiazol novedoso - Google Patents
Derivados de 3- hidroxi-5 -arilisotiazol novedosoInfo
- Publication number
- CO6650337A2 CO6650337A2 CO12106432A CO12106432A CO6650337A2 CO 6650337 A2 CO6650337 A2 CO 6650337A2 CO 12106432 A CO12106432 A CO 12106432A CO 12106432 A CO12106432 A CO 12106432A CO 6650337 A2 CO6650337 A2 CO 6650337A2
- Authority
- CO
- Colombia
- Prior art keywords
- compound
- salt
- ring
- novel
- solvate
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
- C07D275/02—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings
- C07D275/03—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
ProblemaProporcionar un agente que activa GPR40 que tiene, como un ingrediente activo, un compuesto novedoso que tiene una acción agonista GPR40, una sal del compuesto, un solvato de la sal o el compuesto, o similares, particularmente, un secretagogo de insulina y, y un agente terapéutico y/o profiláctico contra diabetes, obesidad, u otras enfermedades.Medios para solucionar el problemaUn compuesto de la Fórmula (I)donde n es 0 hasta 2; p es 0 hasta 4; j es 0 hasta 3; k es 0 hasta 2; un anillo A es un grupo arilo que está opcionalmente sustituido con L o un grupo heterociclico que está opcionalmente sustituido con L; un anillo B es un anillo de benceno, un anillo de piridina, o un anillo de pirimidina;X es O, S, -NR-; y Rhasta Rson grupos específicos, una sal del compuesto, o un solvato de la sal o el compuesto.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2009295855 | 2009-12-25 | ||
JP2010043420 | 2010-02-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
CO6650337A2 true CO6650337A2 (es) | 2013-04-15 |
Family
ID=44195895
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CO12106432A CO6650337A2 (es) | 2009-12-25 | 2012-06-25 | Derivados de 3- hidroxi-5 -arilisotiazol novedoso |
Country Status (25)
Country | Link |
---|---|
US (1) | US8476287B2 (es) |
EP (1) | EP2518060A4 (es) |
JP (2) | JP5002077B2 (es) |
KR (1) | KR20130004262A (es) |
CN (2) | CN104710381A (es) |
AU (1) | AU2010336225A1 (es) |
BR (1) | BR112012015612A2 (es) |
CA (1) | CA2785674A1 (es) |
CL (1) | CL2012001722A1 (es) |
CO (1) | CO6650337A2 (es) |
CR (1) | CR20120345A (es) |
EA (1) | EA201290574A1 (es) |
EC (1) | ECSP12012056A (es) |
GT (1) | GT201200217A (es) |
HN (1) | HN2012001351A (es) |
IL (1) | IL220616A0 (es) |
MA (1) | MA33952B1 (es) |
MX (1) | MX2012007474A (es) |
NI (1) | NI201200113A (es) |
NZ (1) | NZ601408A (es) |
PE (1) | PE20121639A1 (es) |
RU (1) | RU2567755C2 (es) |
SG (1) | SG181961A1 (es) |
WO (1) | WO2011078371A1 (es) |
ZA (1) | ZA201203416B (es) |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2495238A4 (en) | 2009-10-30 | 2013-04-24 | Mochida Pharm Co Ltd | NEW 3-HYDROXY-5-ARYLISOXAZOLE DERIVATIVE |
MX2012007474A (es) | 2009-12-25 | 2012-08-01 | Mochida Pharm Co Ltd | Derivados de 3-hidroxi-5-arilisotiazol novedosos. |
US8581584B2 (en) * | 2010-05-26 | 2013-11-12 | Florida State University Research Foundation | Membrane proteins, mechanisms of action and uses thereof |
WO2012046869A1 (ja) | 2010-10-08 | 2012-04-12 | 持田製薬株式会社 | 環状アミド誘導体 |
EP3243385B1 (en) | 2011-02-25 | 2021-01-13 | Merck Sharp & Dohme Corp. | Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents |
MX2013012520A (es) * | 2011-04-27 | 2014-02-03 | Mochida Pharm Co Ltd | Derivado novedoso de 1-oxido de 3-hidroxi isotiazol. |
JPWO2012147516A1 (ja) * | 2011-04-28 | 2014-07-28 | 持田製薬株式会社 | 環状アミド誘導体 |
WO2013154163A1 (ja) * | 2012-04-11 | 2013-10-17 | 持田製薬株式会社 | 新規5-アリール-1,2-チアジナン誘導体 |
RS61664B1 (sr) | 2012-04-24 | 2021-04-29 | Vertex Pharma | Inhibitori dna-pk |
AU2013290100A1 (en) | 2012-07-11 | 2015-01-29 | Elcelyx Therapeutics, Inc. | Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk |
JP2015525782A (ja) | 2012-08-02 | 2015-09-07 | メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. | 抗糖尿病性三環式化合物 |
CN104994848A (zh) | 2013-02-22 | 2015-10-21 | 默沙东公司 | 抗糖尿病二环化合物 |
RS58374B1 (sr) | 2013-03-12 | 2019-03-29 | Vertex Pharma | Inhibitori dnk-pk |
WO2014139388A1 (en) | 2013-03-14 | 2014-09-18 | Merck Sharp & Dohme Corp. | Novel indole derivatives useful as anti-diabetic agents |
WO2015051496A1 (en) | 2013-10-08 | 2015-04-16 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
EP3057953B1 (en) | 2013-10-17 | 2018-08-15 | Vertex Pharmaceuticals Incorporated | Co-crystals of (s)-n-methyl-8-(1-((2'-methyl-[4,5'-bipyrimidin]-6-yl)amino)propan-2-yl)quinoline-4-carboxamide and deuterated derivatives thereof as dna-pk inhibitors |
US10011609B2 (en) | 2013-11-14 | 2018-07-03 | Cadila Healthcare Limited | Heterocyclic compounds |
RU2701188C2 (ru) * | 2015-02-27 | 2019-09-25 | Нэнтбайосайенс, Инк. | Производные пиримидина в качестве ингибиторов киназы и их терапевтические применения |
JP6616244B2 (ja) * | 2015-05-29 | 2019-12-04 | 北興化学工業株式会社 | 新規なヒドロキシフェニルボロン酸エステルとその製造方法、およびヒドロキシビフェニル化合物の製造法 |
TW201815418A (zh) | 2016-09-27 | 2018-05-01 | Vertex Pharma | 使用dna破壞劑及dna-pk抑制劑之組合治療癌症的方法 |
US11072602B2 (en) | 2016-12-06 | 2021-07-27 | Merck Sharp & Dohme Corp. | Antidiabetic heterocyclic compounds |
US10968232B2 (en) | 2016-12-20 | 2021-04-06 | Merck Sharp & Dohme Corp. | Antidiabetic spirochroman compounds |
PL3752501T3 (pl) | 2018-02-13 | 2023-08-21 | Gilead Sciences, Inc. | Inhibitory pd-1/pd-l1 |
JP7242702B2 (ja) | 2018-04-19 | 2023-03-20 | ギリアード サイエンシーズ, インコーポレイテッド | Pd-1/pd-l1阻害剤 |
KR20230159715A (ko) | 2018-07-13 | 2023-11-21 | 길리애드 사이언시즈, 인코포레이티드 | Pd-1/pd-l1 억제제 |
KR102635333B1 (ko) | 2018-10-24 | 2024-02-15 | 길리애드 사이언시즈, 인코포레이티드 | Pd-1/pd-l1 억제제 |
CN110066254B (zh) * | 2018-11-16 | 2021-03-19 | 温州大学 | 一种异噻唑-3-酮化合物的制备方法 |
JP2022552655A (ja) | 2019-10-07 | 2022-12-19 | キャリーオペ,インク. | Gpr119アゴニスト |
UY39222A (es) | 2020-05-19 | 2021-11-30 | Kallyope Inc | Activadores de la ampk |
EP4172162A4 (en) | 2020-06-26 | 2024-08-07 | Kallyope Inc | AMPK ACTIVATORS |
CN115433143B (zh) * | 2021-06-03 | 2023-10-13 | 中国科学院大连化学物理研究所 | 一种异噻唑啉酮类化合物的合成方法 |
CN115386028B (zh) * | 2022-08-26 | 2023-06-23 | 长春理工大学 | 一种聚合度可控的聚山梨酸-d-薄荷醇酯及合成方法与应用 |
Family Cites Families (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3562283A (en) | 1968-07-01 | 1971-02-09 | Rohm & Haas | 1-oxo and 1,1-dioxo-3-isothiazolones |
US3801575A (en) | 1972-01-24 | 1974-04-02 | Rohm & Haas | 3-hydroxyisothiazoles |
AU711927B2 (en) | 1996-02-27 | 1999-10-21 | Sankyo Company Limited | Isoxazole derivatives |
JP2000204077A (ja) | 1999-01-13 | 2000-07-25 | Warner Lambert Co | ジアリ―ルアミン |
US6545030B1 (en) | 1999-01-13 | 2003-04-08 | Warner-Lambert Company | 1-heterocycle substituted diarylamines |
AU2003263814A1 (en) | 2002-07-26 | 2004-02-16 | Bayer Pharmaceuticals Corporation | Indane, dihydrobenzofuran, and tetrahydronaphthalene carboxylic acid derivatives and their use as antidiabetics |
WO2004022551A1 (ja) | 2002-09-06 | 2004-03-18 | Takeda Pharmaceutical Company Limited | フランまたはチオフェン誘導体およびその医薬用途 |
JP4594611B2 (ja) | 2002-11-08 | 2010-12-08 | 武田薬品工業株式会社 | 受容体機能調節剤 |
WO2004041266A1 (ja) | 2002-11-08 | 2004-05-21 | Takeda Pharmaceutical Company Limited | 受容体機能調節剤 |
US7820837B2 (en) | 2003-05-30 | 2010-10-26 | Takeda Pharmaceutical Company Limited | Condensed ring compound |
WO2005035551A2 (en) | 2003-10-08 | 2005-04-21 | Incyte Corporation | Inhibitors of proteins that bind phosphorylated molecules |
WO2005051890A1 (en) | 2003-11-19 | 2005-06-09 | Smithkline Beecham Corporation | Aminophenylcyclopropyl carboxylic acids and derivatives as agonists to gpr40 |
RU2006126978A (ru) | 2003-12-25 | 2008-01-27 | Такеда Фармасьютикал Компани Лимитед (Jp) | Производные 3-(4-бензилоксифенил)пропановой кислоты |
EP1737809B1 (en) | 2004-02-27 | 2013-09-18 | Amgen, Inc | Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders |
SE0500055D0 (sv) * | 2005-01-10 | 2005-01-10 | Astrazeneca Ab | Therapeutic agents 3 |
MX2008001386A (es) | 2005-08-10 | 2008-04-07 | Takeda Pharmaceutical | Agente terapeutico para diabetes. |
AU2006291234A1 (en) | 2005-09-14 | 2007-03-22 | Amgen Inc. | Conformationally constrained 3- (4-hydroxy-phenyl) - substituted-propanoic acids useful for treating metabolic disorders |
TW200815377A (en) | 2006-04-24 | 2008-04-01 | Astellas Pharma Inc | Oxadiazolidinedione compound |
PT2248812E (pt) | 2006-06-27 | 2014-03-12 | Takeda Pharmaceutical | Compostos cíclicos fundidos como moduladores do receptor gpr40 |
AU2007293028B2 (en) | 2006-09-07 | 2012-05-31 | Amgen Inc. | Heterocyclic GPR40 modulators |
WO2008033931A1 (en) | 2006-09-13 | 2008-03-20 | The Institutes For Pharmaceutical Discovery, Llc | Para-xylylene carboxylic acids and isothiazolones useful as protein tyrosine phosphatases (ptps) in particular ptp-ib |
CA2668713C (en) | 2006-12-01 | 2015-09-08 | Banyu Pharmaceutical Co., Ltd. | Novel phenyl-isoxazol-3-ol derivative |
JP2010524932A (ja) | 2007-04-16 | 2010-07-22 | アムジエン・インコーポレーテツド | 置換ビフェニルフェノキシ−、チオフェニル−及びアミノフェニルプロパン酸gpr40調節物質 |
JP5427784B2 (ja) | 2007-09-21 | 2014-02-26 | サノフイ | (カルボキシルアルキレン−フェニル)−フェニル−オキサルアミド、その製造方法、及び薬剤としてのその使用 |
BRPI0818253A2 (pt) | 2007-10-10 | 2015-04-07 | Amgen Inc | Moduladores de gpr40 bifenil substituídos |
JP2011016722A (ja) | 2007-10-23 | 2011-01-27 | Astellas Pharma Inc | チアゾリジンジオン化合物 |
TW200932219A (en) | 2007-10-24 | 2009-08-01 | Astellas Pharma Inc | Oxadiazolidinedione compound |
CL2008003153A1 (es) | 2007-10-26 | 2009-07-24 | Japan Tobacco Inc | Compuestos espiro condensados, agonistas de gpr40: composicion farmaceutica que comprende a uno de los compuestos; y el uso de los compuestos en la preparacion de medicamentos para el tratamiento de la diabetes, hiperglicemia, alteracion de tolerancia a la glucosa en ayuna, entre otras. |
AU2009220163B2 (en) | 2008-03-06 | 2011-10-06 | Amgen Inc. | Conformationally constrained carboxylic acid derivatives useful for treating metabolic disorders |
JPWO2009147990A1 (ja) | 2008-06-02 | 2011-10-27 | Msd株式会社 | 新規イソオキサゾール誘導体 |
KR20110027657A (ko) | 2008-06-25 | 2011-03-16 | 다이이찌 산쿄 가부시키가이샤 | 카르복실산 화합물 |
JP2012515781A (ja) | 2009-01-23 | 2012-07-12 | シェーリング コーポレイション | 架橋および縮合複素環式抗糖尿病化合物 |
EP2393810A1 (en) | 2009-02-05 | 2011-12-14 | Schering Corporation | Phthalazine-containing antidiabetic compounds |
EP2440541A1 (en) | 2009-06-09 | 2012-04-18 | Takeda Pharmaceutical Company Limited | Novel fused cyclic compound and use thereof |
AR078522A1 (es) | 2009-10-15 | 2011-11-16 | Lilly Co Eli | Compuesto de espiropiperidina, composicion farmaceutica que lo comprende, su uso para preparar un medicamento util para tratar diabetes y compuesto intermediario para su sintesis |
EP2495238A4 (en) | 2009-10-30 | 2013-04-24 | Mochida Pharm Co Ltd | NEW 3-HYDROXY-5-ARYLISOXAZOLE DERIVATIVE |
AR078948A1 (es) | 2009-11-30 | 2011-12-14 | Lilly Co Eli | Compuestos de espiropiperidina, composicion farmaceutica que lo comprenden y su uso para preparar un medicamento util para tratar la diabetes |
MX2012007474A (es) | 2009-12-25 | 2012-08-01 | Mochida Pharm Co Ltd | Derivados de 3-hidroxi-5-arilisotiazol novedosos. |
CN101781268B (zh) | 2010-02-25 | 2012-05-30 | 中国人民解放军军事医学科学院毒物药物研究所 | 异噻唑酮取代的苯二羧酸衍生物及其用于制备β-分泌酶抑制剂的用途 |
WO2012046869A1 (ja) | 2010-10-08 | 2012-04-12 | 持田製薬株式会社 | 環状アミド誘導体 |
-
2010
- 2010-12-24 MX MX2012007474A patent/MX2012007474A/es active IP Right Grant
- 2010-12-24 EP EP10839599.7A patent/EP2518060A4/en not_active Withdrawn
- 2010-12-24 CN CN201510033003.XA patent/CN104710381A/zh active Pending
- 2010-12-24 AU AU2010336225A patent/AU2010336225A1/en not_active Abandoned
- 2010-12-24 SG SG2012047601A patent/SG181961A1/en unknown
- 2010-12-24 CA CA2785674A patent/CA2785674A1/en not_active Abandoned
- 2010-12-24 RU RU2012131840/04A patent/RU2567755C2/ru not_active IP Right Cessation
- 2010-12-24 BR BR112012015612A patent/BR112012015612A2/pt not_active IP Right Cessation
- 2010-12-24 MA MA35101A patent/MA33952B1/fr unknown
- 2010-12-24 WO PCT/JP2010/073464 patent/WO2011078371A1/ja active Application Filing
- 2010-12-24 US US13/392,350 patent/US8476287B2/en not_active Expired - Fee Related
- 2010-12-24 KR KR1020127019581A patent/KR20130004262A/ko not_active Application Discontinuation
- 2010-12-24 CN CN201080059173.0A patent/CN102712610B/zh not_active Expired - Fee Related
- 2010-12-24 EA EA201290574A patent/EA201290574A1/ru unknown
- 2010-12-24 NZ NZ601408A patent/NZ601408A/en not_active IP Right Cessation
- 2010-12-24 PE PE2012000884A patent/PE20121639A1/es not_active Application Discontinuation
- 2010-12-24 JP JP2011547676A patent/JP5002077B2/ja not_active Expired - Fee Related
-
2012
- 2012-05-10 ZA ZA2012/03416A patent/ZA201203416B/en unknown
- 2012-05-17 JP JP2012113868A patent/JP2012153726A/ja active Pending
- 2012-06-22 CL CL2012001722A patent/CL2012001722A1/es unknown
- 2012-06-24 IL IL220616A patent/IL220616A0/en unknown
- 2012-06-25 CO CO12106432A patent/CO6650337A2/es not_active Application Discontinuation
- 2012-06-25 CR CR20120345A patent/CR20120345A/es unknown
- 2012-06-25 GT GT201200217A patent/GT201200217A/es unknown
- 2012-06-25 HN HN2012001351A patent/HN2012001351A/es unknown
- 2012-06-25 NI NI201200113A patent/NI201200113A/es unknown
- 2012-07-23 EC ECSP12012056 patent/ECSP12012056A/es unknown
Also Published As
Publication number | Publication date |
---|---|
CN102712610A (zh) | 2012-10-03 |
EP2518060A1 (en) | 2012-10-31 |
CL2012001722A1 (es) | 2012-12-14 |
KR20130004262A (ko) | 2013-01-09 |
ECSP12012056A (es) | 2012-10-30 |
JP2012153726A (ja) | 2012-08-16 |
GT201200217A (es) | 2014-02-10 |
JPWO2011078371A1 (ja) | 2013-05-09 |
ZA201203416B (en) | 2013-08-28 |
US20120157459A1 (en) | 2012-06-21 |
WO2011078371A1 (ja) | 2011-06-30 |
EP2518060A4 (en) | 2014-01-08 |
CN104710381A (zh) | 2015-06-17 |
MX2012007474A (es) | 2012-08-01 |
MA33952B1 (fr) | 2013-01-02 |
JP5002077B2 (ja) | 2012-08-15 |
RU2012131840A (ru) | 2014-01-27 |
CN102712610B (zh) | 2015-03-04 |
EA201290574A1 (ru) | 2012-12-28 |
BR112012015612A2 (pt) | 2016-03-15 |
HN2012001351A (es) | 2015-03-23 |
IL220616A0 (en) | 2012-08-30 |
CA2785674A1 (en) | 2011-06-30 |
CR20120345A (es) | 2012-11-01 |
RU2567755C2 (ru) | 2015-11-10 |
NZ601408A (en) | 2013-12-20 |
SG181961A1 (en) | 2012-08-30 |
NI201200113A (es) | 2012-08-13 |
US8476287B2 (en) | 2013-07-02 |
AU2010336225A1 (en) | 2012-08-16 |
PE20121639A1 (es) | 2012-12-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO6650337A2 (es) | Derivados de 3- hidroxi-5 -arilisotiazol novedoso | |
CY1121144T1 (el) | Ετεροκυκλικες ενωσεις και χρησεις αυτων | |
BR112013027883A2 (pt) | novo derivado de 1-óxido de 3-hidroxiisotiazol | |
PE20180449A1 (es) | Derivado de glucagon y una composicion que comprende un conjugado de accion prolongada del mismo | |
CL2011001497A1 (es) | Compuestos derivados de heterociclos, modulador de gpr120; composicion farmaceutica; y su uso para el tratamiento de diabetes tipo i,ii y sindrome metabolico. | |
CR20120177A (es) | Nuevos compuestos de espiropiperidina y el uso farmacéutico del mismo para el tratamiento de diabetes | |
CU20170009A7 (es) | 2-(morfolin-4-il)-1,7-naftiridinas útiles en el tratamiento o la profilaxis de enfermedades hiperproliferativas | |
UA114710C2 (uk) | Похідне оксинтомодуліну та фармацевтична композиція для запобігання або лікування ожиріння, яка його містить | |
BR112016018548A2 (pt) | composto, ácido, medicamento, e, uso de um composto. | |
CO2017006308A2 (es) | Derivados de glucagón | |
CO6612267A2 (es) | Nuevos derivados de 1,1 dióxido- 5 fenil- 2,3,4-5tetrahidro- 1,4-benzotiazepina y composiciones farmaceúticas que los comprenden | |
CR10564A (es) | Compuestos cíclicos fusionados | |
CR20120296A (es) | Nuevos compuestos de espiropiperidina | |
TN2013000413A1 (en) | Glycoside derivatives and their uses for the treatment of diabetes | |
CR20140005A (es) | Una nueva composición terapéutica que contiene apomorfina como principio activo | |
CL2011003079A1 (es) | Compuestos derivados aromaticos o heteroaromaticos de heterociclos nitrogenados de oxima, agonista de receptor gpr119; composicion farmaceutica que comprende dichos compuestos; y su uso para el tratamiento de enfermedades mediadas por la modulacion de dicha actividad, como obecidad y diabetes. | |
BR112017016817A2 (pt) | derivados heterocíclicos formilados como inibidores de fgfr4 | |
PA8846201A1 (es) | Derivados de anilina-pirimidina sustituidos con sulfoximina como inhibidores de quinasas dependientes de ciclina (cdk), producción y uso de los mismos como productos medicinales | |
PH12019500467A1 (en) | Benzo-fused heterocyclic derivatives useful agonists of gpr120 | |
DOP2012000058A (es) | Agente terapeutico para trastornos del estado de animo | |
CL2011002181A1 (es) | Compuestos ciclicos o heterociclicos (n,o,s) de derivados de fenil (heterociclil) fenil (metil,etil) amina, agonistas de gpr119 e inhibidores de dpp-iv; composicion farmaceutica; y su uso para el tratamiento de la diabetes tipo ii, obesidad, sindrome metabolico, tolerancia a la glucosa e hiperlipidemia, entre otras enfermedades. | |
CL2011002650A1 (es) | Composicion que comprende n-(4-(2-furil)-5-(tetrahidropiran-4-ilcarbonil)tiazol-2-il)-2-metilpiridin-5-carboxamida y l-dopa; uso del compuesto para el tratamiento de un trastorno del movimiento secundario de la terapia con l-dopa; uso del compuesto y l-dopa y/o para el tratamiento y/o profilaxis de la enfermedad de parkinson. | |
AR095032A1 (es) | Formulaciones de compuestos orgánicos, composición farmacéutica sólida comprimida por rodillo | |
CL2009000949A1 (es) | Compuestos derivados de 1,2,3,5-tetrahidro-indolizina, 6,7,8,9-tetrahidro-4h-quinolizina sustituidos, inhibidores de la actividad de cinasa de mek; su composicion farmaceutica; su uso para el tratamiento de enfermedades hiperproliferativas, tal como cancer e inflamaciones. | |
CY1119483T1 (el) | Θεραπευτικος παραγων για τις αγχωδεις διαταραχες |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Application refused |